Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $225
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $220 to $225.
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $220 to $225.